Saudi German Health’s H1 2022 profit rises 46% to SAR 31 mln; Q2 at SAR 10.4 mln

07/08/2022 Argaam Exclusive

View other reports

Middle East Healthcare Co. (Saudi German Health) reported a 46% increase in H1 2022 net profit after Zakat and tax to SAR 31 million, compared to SAR 21.2 million in the year-ago period.

Financials (M)

Item	6m 2021	6m 2022	Change‬
Revenues	874.94	1,021.41	16.7 %
Gross Income	275.80	323.79	17.4 %
Operating Income	20.08	57.05	184.1 %
Net Income	21.24	30.92	45.6 %
Average Shares	92.04	92.04	-
EPS (Riyals)	0.23	0.34	45.6 %

The profit growth was driven by an increase in revenue as the healthcare services provider revised prices with key clients, due to changes in the pricing and case mix.

In Q2 2022, net profit after Zakat and tax climbed 14.1% to SAR 10.4 million, from SAR 9.14 million in the corresponding period of 2021. Last year, there was a decrease in the volume of business with one of the key clients, which was later restored. Dammam Hospital’s business is also ramping up amid a change in the pricing and case mix.

On a quarterly basis, the second-quarter net profit fell by 49.1% from SAR 20.49 million on a drop in doing business during the holy month of Ramadan and the holiday season. This is besides the initial operating cost of two new healthcare facilities: Hay Al Jamea Hospital in Jeddah and Abha Clinics in Asir. Selling and marketing expenses also rose quarter-on-quarter (QoQ.)

Current Quarter Comparison (M)

Compared With The

Item	Q2 2021	Q2 2022	Change‬
Revenues	456.57	508.09	11.3 %
Gross Income	152.64	158.77	4.0 %
Operating Income	20.12	21.77	8.2 %
Net Income	9.14	10.43	14.1 %
Average Shares	92.04	92.04	-
EPS (Riyals)	0.10	0.11	14.1 %

Item	Q1 2022	Q2 2022	Change‬
Revenues	513.32	508.09	(1.0 %)
Gross Income	165.02	158.77	(3.8 %)
Operating Income	35.28	21.77	(38.3 %)
Net Income	20.49	10.43	(49.1 %)
Average Shares	92.04	92.04	-
EPS (Riyals)	0.22	0.11	(49.1 %)

Shareholders’ equity, after minority interest, rose to SAR 1.281 billion as of June 30, 2022, from SAR 1.252 billion a year earlier.

During the same period, Saudi German Health’s share in Hail National Healthcare Co. jumped from 47% to 53.89% through increased investment in the company's business.

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2013	-	-	-	-	-	-
Q2 2013	-	-	-	-	-	-
Q3 2013	-	-	-	-	-	-
Q4 2013	-	-	-	-	-	-
2013	828.36	52.8 %	430.49	73.3 %	136.85	88.6 %
Q1 2014	359.18	-	199.49	-	75.11	-
Q2 2014	347.08	-	185.78	-	88.17	-
Q3 2014	323.16	-	174.49	-	71.53	-
Q4 2014	369.34	-	190.01	-	78.37	-
2014	1,398.75	68.9 %	749.76	74.2 %	313.18	128.8 %
Q1 2015	391.64	9.0 %	208.99	4.8 %	102.89	37.0 %
Q2 2015	372.00	7.2 %	203.88	9.7 %	89.24	1.2 %
Q3 2015	352.20	9.0 %	183.23	5.0 %	88.21	23.3 %
Q4 2015	418.69	13.4 %	214.04	12.6 %	97.86	24.9 %
2015	1,534.53	9.7 %	810.13	8.1 %	378.20	20.8 %
Q1 2016	421.52	7.6 %	216.62	3.7 %	103.68	0.8 %
Q2 2016	410.07	10.2 %	212.49	4.2 %	76.56	(14.2 %)
Q3 2016	379.09	7.6 %	199.40	8.8 %	91.10	3.3 %
Q4 2016	404.96	(3.3 %)	199.88	(6.6 %)	87.04	(11.1 %)
2016	1,615.64	5.3 %	828.39	2.3 %	358.37	(5.2 %)
Q1 2017	393.53	(6.6 %)	180.47	(16.7 %)	107.04	3.2 %
Q2 2017	351.28	(14.3 %)	138.63	(34.8 %)	58.97	(23.0 %)
Q3 2017	352.98	(6.9 %)	133.30	(33.1 %)	55.70	(38.9 %)
Q4 2017	364.60	(10.0 %)	145.47	(27.2 %)	73.06	(16.1 %)
2017	1,462.39	(9.5 %)	597.87	(27.8 %)	294.77	(17.7 %)
Q1 2018	395.11	0.4 %	160.42	(11.1 %)	85.82	(19.8 %)
Q2 2018	346.13	(1.5 %)	116.91	(15.7 %)	31.66	(46.3 %)
Q3 2018	338.77	(4.0 %)	111.87	(16.1 %)	21.29	(61.8 %)
Q4 2018	310.68	(14.8 %)	111.56	(23.3 %)	23.96	(67.2 %)
2018	1,390.69	(4.9 %)	500.75	(16.2 %)	162.73	(44.8 %)
Q1 2019	350.18	(11.4 %)	101.63	(36.6 %)	18.31	(78.7 %)
Q2 2019	353.20	2.0 %	102.76	(12.1 %)	7.58	(76.0 %)
Q3 2019	386.76	14.2 %	119.96	7.2 %	33.31	56.5 %
Q4 2019	406.51	30.8 %	148.59	33.2 %	44.06	83.9 %
2019	1,496.65	7.6 %	472.93	(5.6 %)	103.27	(36.5 %)
Q1 2020	436.31	24.6 %	146.86	44.5 %	24.36	33.0 %
Q2 2020	373.26	5.7 %	120.49	17.3 %	23.73	212.9 %
Q3 2020	492.13	27.2 %	171.91	43.3 %	42.12	26.4 %
Q4 2020	448.89	10.4 %	139.12	(6.4 %)	17.20	(61.0 %)
2020	1,750.59	17.0 %	578.37	22.3 %	107.41	4.0 %
Q1 2021	418.37	(4.1 %)	123.16	(16.1 %)	(0.04)	(100.2 %)
Q2 2021	456.57	22.3 %	152.64	26.7 %	20.12	(15.2 %)
Q3 2021	498.73	1.3 %	172.27	0.2 %	27.46	(34.8 %)
Q4 2021	498.95	11.2 %	160.11	15.1 %	(7.03)	(140.9 %)
2021	1,872.62	7.0 %	608.18	5.2 %	40.50	(62.3 %)
Q1 2022	513.32	22.7 %	165.02	34.0 %	35.28	90551.0 %
Q2 2022	508.09	11.3 %	158.77	4.0 %	21.77	8.2 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2012	542.22	24.1 %	248.36	55.2 %	72.56	77.0 %
2013	828.36	52.8 %	430.49	73.3 %	136.85	88.6 %
2014	1,398.75	68.9 %	749.76	74.2 %	313.18	128.8 %
2015	1,534.53	9.7 %	810.13	8.1 %	378.20	20.8 %
2016	1,615.64	5.3 %	828.39	2.3 %	358.37	(5.2 %)
2017	1,462.39	(9.5 %)	597.87	(27.8 %)	294.77	(17.7 %)
2018	1,390.69	(4.9 %)	500.75	(16.2 %)	162.73	(44.8 %)
2019	1,496.65	7.6 %	472.93	(5.6 %)	103.27	(36.5 %)
2020	1,750.59	17.0 %	578.37	22.3 %	107.41	4.0 %
2021	1,872.62	7.0 %	608.18	5.2 %	40.50	(62.3 %)

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2013	-	-	-	-	-	-
Q2 2013	-	-	-	-	-	-
Q3 2013	-	-	-	-	-	-
Q4 2013	-	-	-	-	-	-
2013	137.20	121.3 %	1.49	-	137.20	1.49
Q1 2014	80.16	-	0.87	-	80.16	0.87
Q2 2014	92.80	-	1.01	-	92.80	1.01
Q3 2014	74.36	-	0.81	-	74.36	0.81
Q4 2014	84.64	-	0.92	-	84.64	0.92
2014	331.97	142.0 %	3.61	-	331.97	3.61
Q1 2015	105.39	31.5 %	1.15	-	105.39	1.15
Q2 2015	91.79	(1.1 %)	1.00	-	91.79	1.00
Q3 2015	90.75	22.0 %	0.99	-	90.75	0.99
Q4 2015	102.32	20.9 %	1.11	-	102.32	1.11
2015	390.25	17.6 %	4.24	-	390.25	4.24
Q1 2016	104.20	(1.1 %)	1.13	-	104.20	1.13
Q2 2016	74.07	(19.3 %)	0.80	-	74.07	0.80
Q3 2016	99.64	9.8 %	1.08	-	99.64	1.08
Q4 2016	84.73	(17.2 %)	0.92	-	84.73	0.92
2016	362.64	(7.1 %)	3.94	-	362.64	3.94
Q1 2017	109.97	5.5 %	1.19	-	109.97	1.19
Q2 2017	61.95	(16.4 %)	0.67	-	61.95	0.67
Q3 2017	64.88	(34.9 %)	0.70	-	64.88	0.70
Q4 2017	82.69	(2.4 %)	0.90	-	82.69	0.90
2017	319.49	(11.9 %)	3.47	-	319.49	3.47
Q1 2018	87.13	(20.8 %)	0.95	-	87.13	0.95
Q2 2018	34.27	(44.7 %)	0.37	-	34.27	0.37
Q3 2018	20.16	(68.9 %)	0.22	-	20.16	0.22
Q4 2018	30.69	(62.9 %)	0.33	-	30.69	0.33
2018	172.25	(46.1 %)	1.87	-	172.25	1.87
Q1 2019	14.59	(83.3 %)	0.16	-	14.59	0.16
Q2 2019	12.28	(64.2 %)	0.13	-	12.28	0.13
Q3 2019	33.23	64.8 %	0.36	-	33.23	0.36
Q4 2019	37.47	22.1 %	0.41	(8.00)	45.47	0.49
2019	97.57	(43.4 %)	1.06	(8.00)	105.57	1.15
Q1 2020	21.18	45.2 %	0.23	-	21.18	0.23
Q2 2020	16.35	33.2 %	0.18	-	16.35	0.18
Q3 2020	34.91	5.1 %	0.38	-	34.91	0.38
Q4 2020	9.54	(74.5 %)	0.10	-	9.54	0.10
2020	81.99	(16.0 %)	0.89	-	81.99	0.89
Q1 2021	12.10	(42.9 %)	0.13	17.53	(5.43)	(0.06)
Q2 2021	9.14	(44.1 %)	0.10	(0.48)	9.62	0.10
Q3 2021	14.35	(58.9 %)	0.16	(4.16)	18.51	0.20
Q4 2021	(18.39)	(292.8 %)	(0.20)	0.84	(19.24)	(0.21)
2021	17.20	(79.0 %)	0.19	13.74	3.46	0.04
Q1 2022	20.49	69.3 %	0.22	-	20.49	0.22
Q2 2022	10.43	14.1 %	0.11	-	10.43	0.11

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2012	61.99	72.2 %	0.67	-	61.99	0.67
2013	137.20	121.3 %	1.49	-	137.20	1.49
2014	331.97	142.0 %	3.61	-	331.97	3.61
2015	390.25	17.6 %	4.24	-	390.25	4.24
2016	362.64	(7.1 %)	3.94	-	362.64	3.94
2017	319.49	(11.9 %)	3.47	-	319.49	3.47
2018	172.25	(46.1 %)	1.87	-	172.25	1.87
2019	97.57	(43.4 %)	1.06	(8.00)	105.57	1.15
2020	81.99	(16.0 %)	0.89	-	81.99	0.89
2021	17.20	(79.0 %)	0.19	13.74	3.46	0.04

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2013	-	-	-
Q2 2013	-	-	-
Q3 2013	-	-	-
Q4 2013	-	-	-
2013	51.97 %	21.68 %	16.56 %
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	53.60 %	25.57 %	23.73 %
2014	53.60 %	25.57 %	23.73 %
Q1 2015	53.05 %	27.10 %	24.96 %
Q2 2015	53.39 %	26.84 %	24.46 %
Q3 2015	52.93 %	27.56 %	25.09 %
Q4 2015	52.79 %	28.05 %	25.43 %
2015	52.79 %	28.05 %	25.43 %
Q1 2016	52.27 %	27.77 %	24.87 %
Q2 2016	51.57 %	26.50 %	23.17 %
Q3 2016	51.71 %	26.41 %	23.34 %
Q4 2016	51.27 %	26.12 %	22.45 %
2016	51.27 %	26.12 %	22.45 %
Q1 2017	49.90 %	26.91 %	23.20 %
Q2 2017	46.99 %	27.02 %	23.30 %
Q3 2017	43.41 %	25.39 %	21.40 %
Q4 2017	40.88 %	25.40 %	21.85 %
2017	40.88 %	25.40 %	21.85 %
Q1 2018	39.47 %	24.17 %	20.26 %
Q2 2018	38.12 %	22.54 %	18.44 %
Q3 2018	37.01 %	20.57 %	15.52 %
Q4 2018	36.01 %	18.10 %	12.39 %
2018	36.01 %	18.10 %	12.39 %
Q1 2019	32.84 %	13.74 %	7.41 %
Q2 2019	31.62 %	12.25 %	5.74 %
Q3 2019	31.12 %	12.85 %	6.48 %
Q4 2019	31.60 %	13.48 %	7.05 %
2019	31.60 %	13.48 %	7.05 %
Q1 2020	32.74 %	13.41 %	7.09 %
Q2 2020	33.43 %	14.66 %	7.25 %
Q3 2020	34.41 %	14.80 %	6.90 %
Q4 2020	33.04 %	13.40 %	4.68 %
2020	33.04 %	13.40 %	4.68 %
Q1 2021	32.01 %	12.65 %	3.20 %
Q2 2021	32.32 %	11.91 %	2.68 %
Q3 2021	32.22 %	11.12 %	1.77 %
Q4 2021	32.48 %	9.71 %	0.18 %
2021	32.48 %	9.71 %	0.18 %
Q1 2022	33.04 %	10.93 %	1.49 %
Q2 2022	32.50 %	10.71 %	1.50 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2012	45.80 %	20.53 %	11.43 %
2013	51.97 %	21.68 %	16.56 %
2014	53.60 %	25.57 %	23.73 %
2015	52.79 %	28.05 %	25.43 %
2016	51.27 %	26.12 %	22.45 %
2017	40.88 %	25.40 %	21.85 %
2018	36.01 %	18.10 %	12.39 %
2019	31.60 %	13.48 %	7.05 %
2020	33.04 %	13.40 %	4.68 %
2021	32.48 %	9.71 %	0.18 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2013	-	-	-
Q2 2013	-	-	-
Q3 2013	-	-	-
Q4 2013	-	-	-
Q1 2014	55.54 %	23.76 %	22.32 %
Q2 2014	53.53 %	28.54 %	26.74 %
Q3 2014	54.00 %	25.72 %	23.01 %
Q4 2014	51.45 %	24.43 %	22.92 %
Q1 2015	53.36 %	29.47 %	26.91 %
Q2 2015	54.81 %	27.44 %	24.67 %
Q3 2015	52.02 %	28.83 %	25.77 %
Q4 2015	51.12 %	26.62 %	24.44 %
Q1 2016	51.39 %	28.30 %	24.72 %
Q2 2016	51.82 %	22.50 %	18.06 %
Q3 2016	52.60 %	28.28 %	26.29 %
Q4 2016	49.36 %	25.48 %	20.92 %
Q1 2017	45.86 %	31.64 %	27.94 %
Q2 2017	39.46 %	22.25 %	17.64 %
Q3 2017	37.76 %	21.46 %	18.38 %
Q4 2017	39.90 %	25.53 %	22.68 %
Q1 2018	40.60 %	27.04 %	22.05 %
Q2 2018	33.78 %	15.35 %	9.90 %
Q3 2018	33.02 %	13.01 %	5.95 %
Q4 2018	35.91 %	15.33 %	9.88 %
Q1 2019	29.02 %	11.44 %	4.17 %
Q2 2019	29.09 %	9.62 %	3.48 %
Q3 2019	31.02 %	15.07 %	8.59 %
Q4 2019	36.55 %	17.05 %	11.18 %
Q1 2020	33.66 %	11.59 %	4.85 %
Q2 2020	32.28 %	15.23 %	4.38 %
Q3 2020	34.93 %	15.45 %	7.09 %
Q4 2020	30.99 %	11.40 %	2.13 %
Q1 2021	29.44 %	8.41 %	(1.30 %)
Q2 2021	33.43 %	11.79 %	2.11 %
Q3 2021	34.54 %	12.53 %	3.71 %
Q4 2021	32.09 %	6.10 %	(3.86 %)
Q1 2022	32.15 %	13.30 %	3.99 %
Q2 2022	31.25 %	10.84 %	2.05 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2013	-	-	-	-
Q2 2013	-	-	-	-
Q3 2013	-	-	-	-
Q4 2013	-	-	-	-
Q1 2014	92.04	-	-	10.70
Q2 2014	92.04	-	-	11.69
Q3 2014	92.04	-	-	12.48
Q4 2014	92.04	3.61	3.61	12.38
Q1 2015	92.04	3.88	3.88	13.50
Q2 2015	92.04	3.87	3.87	12.67
Q3 2015	92.04	4.05	4.05	13.63
Q4 2015	92.04	4.24	4.24	14.70
Q1 2016	92.04	4.23	4.23	16.39
Q2 2016	92.04	4.03	4.03	15.20
Q3 2016	92.04	4.13	4.13	16.43
Q4 2016	92.04	3.94	3.94	17.32
Q1 2017	92.04	4.00	4.00	18.46
Q2 2017	92.04	3.87	3.87	17.09
Q3 2017	92.04	3.49	3.49	17.74
Q4 2017	92.04	3.47	3.47	15.75
Q1 2018	92.04	3.22	3.22	16.69
Q2 2018	92.04	2.92	2.92	15.07
Q3 2018	92.04	2.44	2.44	15.29
Q4 2018	92.04	1.87	1.87	15.71
Q1 2019	92.04	1.08	1.08	15.87
Q2 2019	92.04	0.84	0.84	16.00
Q3 2019	92.04	0.99	0.99	16.36
Q4 2019	92.04	1.06	1.15	16.54
Q1 2020	92.04	1.13	1.22	16.77
Q2 2020	92.04	1.18	1.26	16.95
Q3 2020	92.04	1.19	1.28	17.33
Q4 2020	92.04	0.89	0.89	13.38
Q1 2021	92.04	0.79	0.60	13.51
Q2 2021	92.04	0.71	0.53	13.61
Q3 2021	92.04	0.49	0.35	13.77
Q4 2021	92.04	0.19	0.04	13.66
Q1 2022	92.04	0.28	0.32	13.89
Q2 2022	92.04	0.29	0.33	13.92

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2012	92.04	0.67	0.67	6.65
2013	92.04	1.49	1.49	9.84
2014	92.04	3.61	3.61	12.38
2015	92.04	4.24	4.24	14.70
2016	92.04	3.94	3.94	17.32
2017	92.04	3.47	3.47	15.75
2018	92.04	1.87	1.87	15.71
2019	92.04	1.06	1.15	16.54
2020	92.04	0.89	0.89	13.38
2021	92.04	0.19	0.04	13.66

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2013	-	-	-
Q2 2013	-	-	-
Q3 2013	-	-	-
Q4 2013	-	-	-
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	17.17	17.17	4.43
Q2 2016	17.16	17.16	4.56
Q3 2016	12.41	12.41	3.12
Q4 2016	18.62	18.62	4.23
Q1 2017	18.48	18.48	4.01
Q2 2017	19.45	19.45	4.41
Q3 2017	17.98	17.98	3.54
Q4 2017	15.52	15.52	3.42
Q1 2018	17.90	17.90	3.46
Q2 2018	20.02	20.02	3.88
Q3 2018	15.00	15.00	2.39
Q4 2018	17.34	17.34	2.07
Q1 2019	29.49	29.49	2.01
Q2 2019	32.63	32.63	1.72
Q3 2019	26.36	26.36	1.59
Q4 2019	28.02	25.89	1.80
Q1 2020	22.49	20.89	1.52
Q2 2020	25.77	23.99	1.79
Q3 2020	30.69	28.61	2.11
Q4 2020	39.35	39.35	2.62
Q1 2021	44.44	58.50	2.60
Q2 2021	54.85	74.08	2.88
Q3 2021	77.28	More than 100	2.75
Q4 2021	More than 100	More than 100	2.32
Q1 2022	More than 100	More than 100	2.34
Q2 2022	More than 100	98.17	2.31

Period	P/E	Adjusted P/E	Price/book
2012	-	-	-
2013	-	-	-
2014	-	-	-
2015	-	-	-
2016	18.62	18.62	4.23
2017	15.52	15.52	3.42
2018	17.34	17.34	2.07
2019	28.02	25.89	1.80
2020	39.34	39.34	2.62
2021	More than 100	More than 100	2.32

Business Segments (Million)

Compared With The

Period	Inpatient clinics	Outpatient clinics	Pharmacy Sales	Others
Q1 2014	207.07	85.01	64.94	2.16
Q2 2014	200.50	77.40	66.66	2.51
Q1 2015	224.99	91.95	70.24	4.46
Q2 2015	211.41	86.64	70.30	3.65
Q3 2015	200.38	85.53	63.54	2.76
Q4 2015	220.47	119.55	72.94	5.72
Q1 2016	241.22	100.20	73.04	7.06
Q2 2016	229.99	99.85	72.93	7.31
Q3 2016	224.32	89.88	62.16	2.72
Q4 2016	220.91	107.73	72.64	3.69
Q1 2017	242.80	104.89	71.94	4.27
Q2 2017	224.48	92.89	70.77	3.54
Q3 2017	133.39	85.39	60.16	3.27
Q4 2017	172.44	114.51	71.35	6.30
Q1 2018	214.32	109.10	68.50	3.20
Q2 2018	188.62	79.63	76.10	1.78
Q3 2018	184.16	98.93	53.64	2.04
Q4 2018	147.36	97.71	61.91	3.70
Q1 2019	181.07	97.28	67.29	4.54
Q2 2019	185.66	95.13	68.96	3.44
Q3 2019	223.51	95.92	64.81	2.51
Q4 2019	222.02	111.18	69.80	3.51
Q1 2020	264.27	98.09	71.34	2.60
Q2 2020	238.16	70.59	61.71	2.81
Q3 2020	301.73	111.20	76.35	2.85
Q4 2020	281.15	110.99	74.56	3.81
Q1 2021	236.94	115.00	61.88	4.54
Q2 2021	284.69	102.17	67.31	2.40
Q3 2021	292.19	139.00	61.71	5.83
Q4 2021	284.48	135.06	74.52	4.89
Q1 2022	290.29	141.03	78.90	3.10
Q2 2022	294.67	138.11	73.11	2.20

Period	Inpatient clinics	Outpatient clinics	Pharmacy Sales	Others
2013	-	-	159.08	1.19
2014	807.92	323.31	257.32	10.20
2015	857.25	383.67	277.02	16.59
2016	916.44	397.66	280.76	20.77
2017	773.12	397.68	274.21	17.38
2018	734.45	385.37	260.14	10.73
2019	812.27	399.51	270.86	14.01
2020	1,085.30	390.88	283.96	12.07
2021	1,098.30	491.24	265.42	17.66

Analysts Estimates (Million)

Item	Q2 2022 (e)	Q2 2022 (a)	Change‬
Average	16.57	10.43	(37.1 %)

Estimates vs Actual (Million)

Item	Q2 2022 (e)	Q2 2022 (a)	Change
AlJazira Capital	7.70	10.43	35.4 %
Hermes	20.00	10.43	(47.9) %
SNB Capital	22.00	10.43	(52.6) %

Financial Ratios

	Current
Market Cap (M Riyal)	6,488.82
Enterprise Value (EV) (M)	8,884.32
Shares Outstanding ((M))	92.04
EPS ( Riyal) (TTM)	2.30
Book Value (BV) ( Riyal)	18.46
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	33.80
P/E (TTM)	30.70
Price/book	3.82
Return on Average Assets (%) (TTM)	4.2
Return on Average Equity (%) (TTM)	13.2

Middle East Healthcare Co. (SAUDI GERMAN HEALTH)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Saudi German Health’s H1 2022 profit rises 46% to SAR 31 mln; Q2 at SAR 10.4 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2022 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Middle East Healthcare Co. (SAUDI GERMAN HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Saudi German Health’s H1 2022 profit rises 46% to SAR 31 mln; Q2 at SAR 10.4 mln

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q2 2022

Revenue by Business Segment (Latest) 2022 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Middle East Healthcare Co. (SAUDI GERMAN HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)